Damora Therapeutics, Inc. quarterly report, Q3 FY2020

Business Context and Reporting Period

The filing is a Form 10-Q for the quarter ended September 30, 2020, filed by Galecto, Inc., not “Damora Therapeutics, Inc.” The company is a clinical-stage biotechnology business developing small-molecule inhibitors targeting galectin-3 and LOXL2 for fibrotic diseases and cancer-related indications. Lead candidate GB0139 was in Phase 2b development; GB1211 and GB2064 were in earlier clinical or preclinical development.

The financial statements are unaudited and prepared under U.S. GAAP. Comparability is affected by the December 2019 reorganization and acquisition of PharmAkea: 2020 results reflect Galecto, Inc. and its subsidiaries, while 2019 interim results primarily reflect Galecto Biotech AB.

Financial Performance and Liquidity

MetricThree Months Ended September 30Nine Months Ended September 30
Revenue$0$0
Research and development expense$7.7 million$16.9 million
General and administrative expense$2.5 million$5.5 million
Total operating expenses$10.2 million$22.3 million
Net loss$11.7 million$23.3 million
Net loss attributable to common stockholders$14.4 million$30.9 million
Net loss per common share$55.25 loss$118.89 loss
Cash used in operating activitiesNot separately provided$23.7 million

There was no product revenue, gross profit, or meaningful profit margin because no product had received regulatory approval. The operating loss was $10.2 million for the quarter and $22.3 million for the nine-month period.

  • Cash and cash equivalents were $85.3 million at September 30, 2020, with restricted cash of $0.2 million.
  • Total assets were $98.2 million and total liabilities were $8.9 million. The company reported a stockholders’ deficit of $91.7 million, reflecting $181.0 million of convertible preferred stock and an accumulated deficit of $92.8 million.
  • The company reported no material debt financing or finance lease obligations. Operating lease liabilities were approximately $0.9 million.
  • Financing cash inflows were $95.6 million during the first nine months, including $39.7 million from Series C preferred stock and $55.9 million of net Series D proceeds. Approximately $5.5 million of Series D proceeds remained receivable at September 30.

Material Changes Versus the Prior Comparable Period

  • Third-quarter research and development expense increased 108.2% to $7.7 million from $3.7 million, driven primarily by clinical activities, chemistry/manufacturing/control work, personnel, and consulting costs.
  • Third-quarter general and administrative expense increased 118.3% to $2.5 million from $1.2 million, primarily due to accounting, consulting, and personnel costs associated with building the organization and preparing to operate as a public company.
  • Third-quarter net loss increased 183.8% to $11.7 million from $4.1 million. The comparison was also affected by a $1.5 million foreign-exchange expense in 2020 versus $0.3 million of foreign-exchange income in 2019 and the absence of the $0.4 million preferred-stock tranche valuation gain recorded in 2019.
  • For the first nine months, operating expenses increased 58.2% to $22.3 million and net loss increased 92.5% to $23.3 million.
  • Cash increased substantially from $11.3 million at December 31, 2019 to $85.3 million at September 30, 2020, primarily because of the Series C and Series D financings.
  • The company issued 2.4 million Series D preferred shares in September 2020 for gross proceeds of approximately $64.2 million, or $61.4 million net of issuance costs.

Guidance, Outlook, Risks, and Unusual Items

  • Management expected continued operating losses and increasing research, development, general and administrative, and public-company expenses. It stated that September cash plus approximately $85.7 million of net IPO proceeds received after quarter-end was expected to fund development activities into 2024, subject to assumptions that may prove inaccurate.
  • Additional capital will be required to advance clinical and preclinical programs beyond that period; no committed external funding source was in place.
  • COVID-19 delayed recruitment in the GB0139 Phase 2b IPF trial, led to protocol amendments and increased costs, and delayed initiation of the planned GB1211 Phase 2a NASH trial. Further enrollment, supply-chain, site, manufacturing, and regulatory delays remained possible.
  • After quarter-end, the company completed its IPO, selling 6,342,207 common shares at $15.00 per share for approximately $85.7 million in net proceeds. All outstanding Series B, C, and D preferred shares converted into 18,658,643 common shares. The stock began trading on Nasdaq under GLTO on October 29, 2020.
  • The company completed a 2.59970-for-1 common-stock split effective October 20, 2020; historical share and per-share data were retroactively adjusted.
  • Management concluded that disclosure controls were ineffective as of September 30, 2020 because of previously disclosed material weaknesses in internal control over financial reporting, including deficiencies in the financial close process, U.S. GAAP and SEC reporting expertise, and oversight of third-party service providers.
  • The filing reports no material legal proceedings and no material changes to previously disclosed commitments and contingencies. Contractual lease obligations totaled approximately $1.0 million at September 30, 2020.
  • Key risks include clinical-trial failure or delays, patient-enrollment challenges, regulatory nonapproval, reliance on third-party manufacturers and clinical providers, intellectual-property challenges, competition, COVID-19 effects, future dilution, and the need for additional financing.

Most Important Facts for Investors to Verify

  • Confirm the registrant identity: the supplied metadata names Damora Therapeutics, Inc., while the filing identifies Galecto, Inc. and ticker GLTO.
  • Verify the post-quarter-end IPO proceeds, share issuance, preferred-stock conversion, and resulting fully diluted share count.
  • Assess cash runway against actual clinical-trial spending, particularly the GB0139 Phase 2b program and delayed GB1211 program.
  • Monitor remediation of the material weakness and whether disclosure controls and internal control over financial reporting become effective.
  • Track clinical enrollment, protocol amendments, safety and efficacy data, and expected timing of GB0139 results, which management indicated could become available in 2022.
  • Review future financing needs and potential dilution because management acknowledged that additional funding will be necessary to complete development programs.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.